Page last updated: 2024-11-08

6-ethyl-3-(1h-tetrazol-5-yl)chromone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

6-ethyl-3-(1H-tetrazol-5-yl)chromone: antiallergic agent; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID170896
CHEMBL ID3228631
SCHEMBL ID11550765
MeSH IDM0070166

Synonyms (9)

Synonym
aa-344
aa 344
SCHEMBL11550765
6-ethyl-3-(1h-tetrazol-5-yl)chromone
50743-49-2
6-ethyl-3-(1h-tetrazol-5-yl)-4h-1-benzopyran-4-one
CHEMBL3228631
DTXSID90198788
PD160608
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1123017Antiallergic activity in po dosed rat assessed as inhibition of antigen-induced passive cutaneous anaphylaxis relative to DSCG1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
Development of ethyl 3,4-dihydro-4-oxopyrimido[4,5-b]quinoline-2-carboxylate, a new prototype with oral antiallergy activity.
AID1123012Antiallergic activity in po dosed rat assessed as inhibition of antigen-induced passive cutaneous anaphylaxis1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
Development of ethyl 3,4-dihydro-4-oxopyrimido[4,5-b]quinoline-2-carboxylate, a new prototype with oral antiallergy activity.
AID1123878Antianaphylactic activity in po dosed male Sprague-Dawley rat assessed as inhibition of egg albumin/Bordetella pertussis-induced passive cutaneous anaphylaxis reaction1979Journal of medicinal chemistry, Mar, Volume: 22, Issue:3
Studies on antianaphylactic agents. 6. Synthesis of some metabolites of 6-ethyl-3-(1H-tetrazol-5-yl)chromone and their analogues.
AID1123877Antianaphylactic activity in iv dosed male Sprague-Dawley rat assessed as inhibition of egg albumin/Bordetella pertussis-induced passive cutaneous anaphylaxis reaction1979Journal of medicinal chemistry, Mar, Volume: 22, Issue:3
Studies on antianaphylactic agents. 6. Synthesis of some metabolites of 6-ethyl-3-(1H-tetrazol-5-yl)chromone and their analogues.
AID1145604Antiallergic activity in po dosed Sprague-Dawley rat assessed as inhibition of egg albumin-induced passive cutaneous anaphylaxis administered 5 mins prior to egg albumin challenge measured after 30 mins by Evan blue dye leakage assay1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Studies on antianaphylactic agents. 5. Synthesis of 3-(1H-tetrazol-5-yl)chromones, a new series of antiallergic substances.
AID1145602Antiallergic activity in iv dosed Sprague-Dawley rat assessed as inhibition of egg albumin-induced passive cutaneous anaphylaxis administered immediately prior to egg albumin challenge measured after 30 mins by Evan blue dye leakage assay relative to diso1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Studies on antianaphylactic agents. 5. Synthesis of 3-(1H-tetrazol-5-yl)chromones, a new series of antiallergic substances.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.05

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.05 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.05)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]